Morolimumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1), a key regulator of immune responses. It is primarily investigated for its potential in cancer immunotherapy, as it can enhance the immune system's ability to recognize and attack tumor cells. Morolimumab is designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby promoting T-cell activation and proliferation. This mechanism can lead to increased anti-tumor activity. The substance is characterized by its specificity for PD-1, which is expressed on activated T cells, and its ability to modulate immune responses. As a therapeutic agent, Morolimumab is typically administered via injection and is subject to rigorous clinical trials to evaluate its efficacy and safety in various cancer types. Its development is part of a broader trend in oncology focusing on immune checkpoint inhibitors, which have shown promise in improving patient outcomes in several malignancies.

Morolimumab

202833-07-6: Morolimumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1), a key regulator of immune responses. It is primarily investigated for its potential in cancer immunotherapy, as it can enhance the immune system's ability to recognize and attack tumor cells. Morolimumab is designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby promoting T-cell activation and proliferation. This mechanism can lead to increased anti-tumor activity. The substance is characterized by its specificity for PD-1, which is expressed on activated T cells, and its ability to modulate immune responses. As a therapeutic agent, Morolimumab is typically administered via injection and is subject to rigorous clinical trials to evaluate its efficacy and safety in various cancer types. Its development is part of a broader trend in oncology focusing on immune checkpoint inhibitors, which have shown promise in improving patient outcomes in several malignancies.

Morolimumab, an IgG1 human monoclonal antibody targeting RHD/CD240D, serves as a research tool for immune diseases [1].

<p>A IgG1 human anti-RHD/CD240D monoclonal antibody</p>

CAS 202833-07-6

Morolimumab

Morolimumab

Ref: TM-T81762

Morolimumab

Ref: 3D-CLA1233